237 related articles for article (PubMed ID: 28641921)
1. Genome-wide association and interaction studies of CSF T-tau/Aβ
Li J; Zhang Q; Chen F; Meng X; Liu W; Chen D; Yan J; Kim S; Wang L; Feng W; Saykin AJ; Liang H; Shen L;
Neurobiol Aging; 2017 Sep; 57():247.e1-247.e8. PubMed ID: 28641921
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.
Kim S; Swaminathan S; Shen L; Risacher SL; Nho K; Foroud T; Shaw LM; Trojanowski JQ; Potkin SG; Huentelman MJ; Craig DW; DeChairo BM; Aisen PS; Petersen RC; Weiner MW; Saykin AJ;
Neurology; 2011 Jan; 76(1):69-79. PubMed ID: 21123754
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort.
Cong W; Meng X; Li J; Zhang Q; Chen F; Liu W; Wang Y; Cheng S; Yao X; Yan J; Kim S; Saykin AJ; Liang H; Shen L;
BMC Genomics; 2017 May; 18(1):421. PubMed ID: 28558704
[TBL] [Abstract][Full Text] [Related]
5. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
Elias-Sonnenschein LS; Helisalmi S; Natunen T; Hall A; Paajanen T; Herukka SK; Laitinen M; Remes AM; Koivisto AM; Mattila KM; Lehtimäki T; Verhey FR; Visser PJ; Soininen H; Hiltunen M
PLoS One; 2013; 8(4):e59676. PubMed ID: 23573206
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide epistasis analysis reveals gene-gene interaction network on an intermediate endophenotype P-tau/Aβ
Zhang Q; Liu J; Liu H; Ao L; Xi Y; Chen D
Sci Rep; 2024 Feb; 14(1):3984. PubMed ID: 38368488
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
8. Genome-Wide Epistasis Study of Cerebrospinal Fluid Hyperphosphorylated Tau in ADNI Cohort.
Chen D; Li J; Liu H; Liu X; Zhang C; Luo H; Wei Y; Xi Y; Liang H; Zhang Q
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510227
[TBL] [Abstract][Full Text] [Related]
9. Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.
Alexopoulos P; Guo LH; Kratzer M; Westerteicher C; Kurz A; Perneczky R
Dement Geriatr Cogn Disord; 2011; 32(3):164-70. PubMed ID: 21997402
[TBL] [Abstract][Full Text] [Related]
10. Identifying potential genetic epistasis implicated in Alzheimer's disease via detection of SNP-SNP interaction on quantitative trait CSF Aβ
Li J; Chen D; Liu H; Xi Y; Luo H; Wei Y; Liu J; Liang H; Zhang Q
Neurobiol Aging; 2024 Feb; 134():84-93. PubMed ID: 38039940
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels.
Maxwell TJ; Corcoran C; Del-Aguila JL; Budde JP; Deming Y; Cruchaga C; Goate AM; Kauwe JSK;
Alzheimers Res Ther; 2018 Aug; 10(1):86. PubMed ID: 30153862
[TBL] [Abstract][Full Text] [Related]
12. Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.
Hohman TJ; Dumitrescu L; Barnes LL; Thambisetty M; Beecham G; Kunkle B; Gifford KA; Bush WS; Chibnik LB; Mukherjee S; De Jager PL; Kukull W; Crane PK; Resnick SM; Keene CD; Montine TJ; Schellenberg GD; Haines JL; Zetterberg H; Blennow K; Larson EB; Johnson SC; Albert M; Bennett DA; Schneider JA; Jefferson AL;
JAMA Neurol; 2018 Aug; 75(8):989-998. PubMed ID: 29801024
[TBL] [Abstract][Full Text] [Related]
13. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study.
Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A
J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253
[TBL] [Abstract][Full Text] [Related]
14. Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.
Voyle N; Patel H; Folarin A; Newhouse S; Johnston C; Visser PJ; Dobson RJ; Kiddle SJ;
J Alzheimers Dis; 2017; 55(4):1417-1427. PubMed ID: 27834776
[TBL] [Abstract][Full Text] [Related]
15. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.
Cruchaga C; Kauwe JS; Harari O; Jin SC; Cai Y; Karch CM; Benitez BA; Jeng AT; Skorupa T; Carrell D; Bertelsen S; Bailey M; McKean D; Shulman JM; De Jager PL; Chibnik L; Bennett DA; Arnold SE; Harold D; Sims R; Gerrish A; Williams J; Van Deerlin VM; Lee VM; Shaw LM; Trojanowski JQ; Haines JL; Mayeux R; Pericak-Vance MA; Farrer LA; Schellenberg GD; Peskind ER; Galasko D; Fagan AM; Holtzman DM; Morris JC; ; ; ; Goate AM
Neuron; 2013 Apr; 78(2):256-68. PubMed ID: 23562540
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
Ramos de Matos M; Ferreira C; Herukka SK; Soininen H; Janeiro A; Santana I; Baldeiras I; Almeida MR; Lleó A; Dols-Icardo O; Alcolea D; Benussi L; Binetti G; Paterlini A; Ghidoni R; Nacmias B; Meulenbroek O; van Waalwijk van Doorn LJC; Kuiperi HBJ; Hausner L; Waldemar G; Simonsen AH; Tsolaki M; Gkatzima O; Resende de Oliveira C; Verbeek MM; Clarimon J; Hiltunen M; de Mendonça A; Martins M
J Alzheimers Dis; 2018; 66(2):639-652. PubMed ID: 30320580
[TBL] [Abstract][Full Text] [Related]
17. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
[TBL] [Abstract][Full Text] [Related]
18. Association Between Common Variants of APOE, ABCA7, A2M, BACE1, and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: Data from the PUMCH Dementia Cohort.
Dong L; Mao C; Liu C; Li J; Huang X; Wang J; Lei D; Chu S; Sha L; Xu Q; Peng B; Cui L; Gao J
J Alzheimers Dis; 2022; 85(4):1511-1518. PubMed ID: 34958020
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
Kettunen P; Larsson S; Holmgren S; Olsson S; Minthon L; Zetterberg H; Blennow K; Nilsson S; Sjölander A
J Alzheimers Dis; 2015; 44(4):1313-22. PubMed ID: 25420549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
